Javier Pascual, Miguel Gil-Gil, Paula Proszek, Christoph Zielinski, Alistair Reay, Manuel Ruiz-Borrego, Rosalind Cutts, Eva M Ciruelos Gil, Andrew Feber, Montserrat Muñoz-Mateu, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margeli Vila, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, Yuan Liu, Daniel Fernandez Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C Turner, Miguel Martín
PURPOSE: Prognostic and predictive biomarkers to CDK4/6 inhibitors are lacking. Circulating tumour DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy. Here, we conducted plasma ctDNA profiling in patients from the PEARL trial comparing palbociclib+fulvestrant versus capecitabine to investigate associations between baseline genomic landscape and on-treatment ctDNA dynamics with treatment efficacy. EXPERIMENTAL DESIGN: Correlative blood samples were collected at baseline (C1D1) and prior to treatment (C1D15)...
July 25, 2023: Clinical Cancer Research